Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Drops By 15.9%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 51,900 shares, a decrease of 15.9% from the October 31st total of 61,700 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average trading volume of 34,700 shares, the short-interest ratio is currently 1.5 days.

PharmaCyte Biotech Stock Performance

PMCB stock opened at $1.71 on Monday. The firm has a fifty day moving average price of $1.77 and a 200 day moving average price of $1.88. PharmaCyte Biotech has a fifty-two week low of $1.39 and a fifty-two week high of $2.58. The firm has a market cap of $13.13 million, a PE ratio of 2.59 and a beta of -0.20.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings data on Monday, September 16th. The company reported $0.14 EPS for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.